Role of Sp1 expression in gastric cancer: A meta-analysis and bioinformatics analysis

SHUAI SHI and ZHI-GANG ZHANG

Department of Pathology, Cangzhou People's Hospital, Cangzhou, Hebei 061000, P.R. China

Received December 15, 2018; Accepted July 26, 2019

DOI: 10.3892/ol.2019.10775

Abstract. Sp1 (specificity protein 1) is an important transcription factor that regulates multiple cancer-related genes. A number of published studies have explored the relationship between Sp1 expression and prognosis in gastric cancer. Therefore, a deeper level of understanding is required into the molecular biological mechanism of gastric cancer. Finding new tumor biomarkers for the accurate prediction of occurrence, recurrence and metastasis of gastric cancer are of great significance. The present study uses a systematic meta-analysis and bioinformatics analysis to acquire evidence for a prognosis marker based on Sp1 expression in gastric cancer. A literature search was performed using PubMed and China National Knowledge Infrastructure on 8th June, 2018. A total of 13 studies were included in the meta-analysis. The meta-analysis showed that the expression of Sp1 was significantly higher in gastric cancer tissue, compared with that of normal mucosa [odds ratio (OR), -0.53; 95% CI, -0.62-0.44; P<0.0001] and dysplasia (OR, 0.24; 95% CI, 0.13-0.44; P<0.0001). A positive association was found Sp1 expression and depth of invasion (OR, 0.31; 95% CI, 0.11-0.86), lymph node metastasis (OR, 0.36; 95% CI, 0.22-0.59), TNM staging of gastric cancer (OR, 0.43; 95% CI, 0.24-0.79) and Lauren's classification (OR, 0.83; 95% CI, 0.51-1.36), but not with sex or tumor differentiation (OR, 1.34; 95% CI, 0.95-1.88). According to the Oncomine database, Sp1 mRNA expression is significantly higher in gastric cancer tissues compared with that in normal tissues (P<0.05), including that of intestinal, diffuse and mixed-type gastric carcinomas (P<0.05). Kaplan-Meier plots show that the expression of Sp1 mRNA is negatively associated with overall and progression-free survival rates of patients with gastric cancer, even when stratified according to expression level (P<0.05). The selected prediction parameter is overall survival or progressive-free survival rate. The expression level of Sp1 was divided into high expression group and low expression group according to the best cut off value provided on the Kaplan-Meier plotter. However, Sp1 protein expression is upregulated in gastric cancer tissues compared with normal tissues and is positively associated with depth of invasion and TNM stage of gastric cancer. The high protein expression of Sp1 might make it a good potential marker for the prognosis of patients with gastric cancer.

Introduction

Specificity protein 1 (Sp1) was identified and cloned by Kadonaga et al (1) in 1987, and was one of the earliest transcription factors to be identified. Sp1 belongs to the Sp1/Krüppel-like factor transcription factor family of sequence-specific DNA binding proteins (2). Sp1 consists of four activated functional areas (A, B, C and D). The functional domains A and B are rich in glutumamide. Domain C is a highly-charged amino acid enriched area with three zinc fingers at the end of the hydroxyl group. At the same time, the formation of Sp1 tetramers can attract more polymers that bind to DNA, and produces positive feedback regulation of the transcription process (3). Sp1 performs an important regulatory role for a variety of housekeeping genes, including nucleic acid metabolism related genes and oxidative phosphorylation related genes, including mitogen-activated protein kinase 8 and EPH receptor B2 (4,5). Meanwhile, if the promoter of a gene lacks the expression of the TATA box, Sp1 can prevent DNA methylation and maintain gene transcription at the activation state (3).

It has been proven that Sp1 can upregulate the expression of Bcl-2 (6), survivin (7), and TGF-β (8). Studies have shown that Sp1 can form a compound with the Smad protein to induce the transcription of and overexpression of Smad7, and negatively regulates the TGF-β pathway, thus affecting cell growth, differentiation and apoptosis (9). The abnormal activation of Sp1 can also upregulate the expression of tumor-related factors and angiogenic factors that provide a good microenvironment for tumor growth, and promote tumor proliferation, metastasis and angiogenesis in gastric and pancreatic (10). Sp1 is recruited by the promoter of vascular endothelial growth factor for its upregulated expression, promoting vascular endothelial proliferation, angiogenesis and increasing vascular
Beaver et al. (22) found that the knockdown of Sp1 in mouse embryos, delays the development, causes mutations and may even result in the death of the embryo. Subsequent studies have found that Sp1 plays a key role in the development of the mouse nervous system and male germ cells (23,24). In the present study, a meta-analysis and a bioinformatics analysis was performed to provide evidence for clarifying the relationship between Sp1 expression and clinicopathological factors in gastric cancer.

Materials and methods

Published study search and selection criteria. Articles included in the analysis were searched for on PubMed and China Academic Journal on 8th June 2018 using the key words: Sp1 AND (gastric OR stomach) AND (cancer OR carcinoma OR tumor OR adenocarcinoma). The inclusion criteria for studies included: i) Published Chinese and English literature limited to patients with gastric cancer; ii) the expression of Sp1 detected through immunohistochemistry in patients with gastric cancer and iii) all patients with gastric cancer did not receive radiotherapy or chemotherapy before surgery. The exclusion criteria included: i) Abstracts, case reports, reviews and meeting notes; ii) studies with a small sample size (n<50); iii) repeat publications or repeat data.

Data extraction and quality assessment. As shown in Table I, the information from all eligible publications was extracted by two reviewers, and included the authors, year of publication, patient country, antibody company, number of cases and controls, risks for cancer, and follow-up outcome. The qualities of the studies were independently assessed by the reviewers according to the Newcastle-Ottawa Scale (NOS; http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm). The method consists of sample selection, comparability and ascertainment of outcome as the number of samples, comparability and results will affect the accuracy of the statistical results. Data was extracted from the Kaplan-Meier survival curves using Engauge Digitizer software (version 4.1; markummitchell.github.io/engauge-digitizer) and then their hazard ratios (HR) and corresponding 95% CI were calculated. No disagreements on the studies to be included were found to exist between the two reviewers. Publication bias was evaluated using a funnel plot. Begg's and Egger's tests were used to assess funnel plot asymmetry.

Bioinformatics analysis. Sp1 gene expression level was analyzed using Oncomine (www.oncomine.org), the largest oncogene chip database and integrated data mining platform. There are two analysis methods. Multiple analysis (fold change), where the expression ratio of each gene under two conditions was calculated, generally in the range of 0.5-2.0, and there was no significant differential expression of the gene. T test (P-value), where the gene whose T statistic exceeds a specific value is detected as an abnormality. Whether the analysis is statistically significant by calculating the confidence of the difference. The differences in Sp1 mRNA level were compared between 80 gastric cancer tissues and 80 normal tissues. All data were log-transformed, median centered for each array, and standard deviation was normalized to a single value for each array. Finally, the Kaplan-Meier plots were used to analyze the prognostic significance of Sp1 mRNA expression. The expression level of Sp1 was divided into high expression group and low expression group according to the best cut off value provided on the Kaplan-Meier plotter.

Statistics analysis. Revman (version 5.3; www.cochrane. es/Download/Files/revman.htm) was used for data analysis. Odds ratios and 95% CI were used to estimate the expression of Sp1 based on the clinicopathological parameters of patients with gastric cancer. First, the heterogeneity of the original documents obtained from PubMed and CNKI was determined. If heterogeneity was not significant, the fixed effect model (Mantel-Haenszel method) was applied. If not, the random effect model (Der Simonian and Laird method) was applied. Heterogeneity effect was quantified using the I2 test. According to the cutoff values, heterogeneity was subdivided into low, moderate and high degrees of heterogeneity according to the cut-off values of 25, 50 and 75%, respectively. Publication bias was evaluated using funnel plot and quantified using Begg's test and Egger's test to assess funnel plot asymmetry. Meta-analyses were performed with Revman software 5.3 was analyzed using SPSS software (version 10.0; SPSS, Inc.) and the Student's t-test. Two-sided P<0.05 was considered to indicate a statistically significant difference.

Results

Literature search results. As shown in Fig. 1, duplicate studies, those that had included animal experiments and reviews were excluded by reading the abstracts. A total of 135 articles were initially retrieved, but only 13 articles were found to investigate the relationship between Sp1 expression and clinicopathological or prognostic indicators of gastric cancer. The exclusion criteria were as follows: i) Studies for which only the abstract available and review and conference proceedings; ii) duplicated studies; iii) studies containing western blot, RT-qPCR, cDNA microarray, or transcriptomic sequencing for masep expression; and iv) insufficient data (Fig. 1).

Basic characteristics of included articles. There were 13 articles on the relationship between Sp1 expression and
There were 8 articles that included results of normal gastric tissue (26-33). Finally, there were 4 articles that discussed the prognostic significance of Sp1 expression and its relationship with gastric cancer (25-27,34).

Forest plot of odds ratio (OR) for the association between Sp1 expression and clinicopathological parameters of gastric cancer.

A total of 8 articles included data on 580 patients with gastric cancer and 286 healthy controls. The overall results showed that the expression of Sp1 was upregulated in gastric cancer and dysplasia (Fig. 2A and B), compared with that of normal mucosa tissue. Forest plots of OR for the association of Sp1 expression were divided based on sex (Fig. 2C), depth of invasion (Fig. 2D), lymph node metastasis (Fig. 2E), TNM staging (Fig. 2F) and Lauren's classification (Fig. 2G). The pathological data available in each article varied. Articles were excluded if a particular clinicopathological characteristic was missing. Therefore, the number of articles in the forest map differed from the initial number of articles. The survival data are shown in Fig. 2H, and based on the 4 aforementioned datasets. The relationship between Sp1 expression and decreased survival rate in gastric cancer patients was investigated and found to be significant (HR, 0.32; 95% CI, 0.22-0.46; P<0.0001).

Table I. Characteristics and quality score of the studies.

| Author, year | Country | Ethnicity | Antibody supplier | Cases | Ctrl | Risk of cancer | Follow-up outcome | Quality | (Refs.) |
|--------------|---------|-----------|-------------------|-------|------|---------------|------------------|---------|--------|
| Jiang et al, 2015 | China | Asian | Santa Cruz Biotechnology, Inc. | 227 | - | - | Negative | 8 | (34) |
| Jiang et al, 2009 | China | Asian | Santa Cruz Biotechnology, Inc. | 78 | 20 | Increased | - | 8 | (33) |
| Zhu et al, 2015 | China | Asian | Santa Cruz Biotechnology, Inc. | 95 | 20 | Increased | - | 7 | (32) |
| A et al, 2014 | China | Asian | Cusabio Technology LLC | 66 | 66 | Increased | - | 8 | (31) |
| Cui et al, 2014 | China | Asian | Santa Cruz Biotechnology, Inc. | 105 | - | - | - | 8 | (35) |
| Zhang et al, 2011 | China | Asian | Bioss, Inc. | 76 | 30 | Increased | - | 8 | (30) |
| Zhang et al, 2014 | China | Asian | Shanghai Long Island Biotec. Co., Ltd. | 39 | 39 | Increased | - | 8 | (29) |
| Zhang et al, 2015 | China | Asian | Santa Cruz Biotechnology, Inc. | 64 | 40 | Increased | Negative | 8 | (28) |
| Hua et al, 2013 | China | Asian | Santa Cruz Biotechnology, Inc. | 75 | 14 | Increased | - | 8 | (27) |
| Wang et al, 2003 | China | Asian | Santa Cruz Biotechnology, Inc. | 86 | 57 | Increased | Negative | 8 | (26) |
| Yao et al, 2004 | USA | America | Santa Cruz Biotechnology, Inc. | 86 | - | - | - | 8 | (12) |
| Wei et al, 2009 | China | Asian | Santa Cruz Biotechnology, Inc. | 68 | - | - | Negative | 8 | (25) |
| Hun et al, 2013 | Japan | Asian | Santa Cruz Biotechnology, Inc. | 268 | - | - | - | 8 | (36) |

Ctr, control; -, data not provided.
Publication bias. Publication bias can be quantitatively determined using funnel diagrams, as shown in Fig. 3. Individual studies were removed from the pooled analysis, and then used sensitivity analysis to assess the impact of the individual study on aggregated results. According to Egger's test, this meta-analysis had no apparent publication bias.

The relationship between Sp1 expression and bioinformatics features of gastric cancer. Cui's and D'Errico's datasets showed that Sp1 mRNA expression was higher in gastric cancer tissue compared with that in normal tissues based on bioinformatics features (Fig. 4A, P<0.05), even when stratified as diffuse, intestinal and mixed-type carcinoma (Fig. 4B-D, P<0.05). According to Kaplan-Meier plots (Fig. 4E and F; Table II), higher Sp1 mRNA expression was negatively associated with the overall and progression-free survival rates of all patients with gastric cancer. In addition, in patients who received surgery alone or 5-FU-based chemotherapy, those with T2, N0, N1-3, N1 and N2, M0, intestinal-type moderately-differentiated, or...
Her2-carcinoma were also significantly associated with overall and progression-free survival (P<0.05). Males and T3 patients with gastric cancer with high Sp1 expression showed shorter overall survival times compared with those
with low expression (P<0.05), while only it is significantly associated with overall survival (P<0.05). A similar result was obtained for the progression-free survival rates in patients with T4 cancer (P<0.05).

**Discussion**

Sp1 has a group of zinc-finger proteins that are important transcriptional components in eukaryotic cells, ranging from yeast
It was found to be overexpressed in gastric cancer and associated with a poor outcome (38). Peng et al. (39) found that there is a Sp1 binding site in the promoter region of the dickkopf WNT signaling pathway inhibitor 1 (DKK1) gene and that Sp1 overexpression could increase the activity of the DKK1 promoter. Transcriptional enhancer activator domain 1 was able to increase the expression of Sp1 by binding to its promoter in colorectal cancer cells (40). Shi et al. (41) found that hepatitis B X-interacting protein may activate the fibroblast growth factor 4 promoter via Sp1, which then promotes the migration of breast cancer cells. The transcription activity of Sp1 is enhanced through direct phosphorylation of threonine by p42/p44 mitogen-activated protein kinase (42,43). Jiang et al. (34) reported that the co-expression of erb-b2 receptor tyrosine kinase 2 and Sp1 are independent prognostic factors of patients with gastric cancer. In order to demonstrate the association with Sp1 expression and its clinicopathological significance, 13 studies were analyzed that met specific inclusion criteria and were moderated to ensure high quality according to NOS scores.

Previous studies show that abnormal Sp1 activation may improve the growth, metastasis and dedifferentiation of cells to vertebrate cells (37). It was found to be overexpressed in gastric cancer and associated with a poor outcome (38). Peng et al. (39) found that there is a Sp1 binding site in the promoter region of the dickkopf WNT signaling pathway inhibitor 1 (DKK1) gene and that Sp1 overexpression could increase the activity of the DKK1 promoter. Transcriptional enhancer activator domain 1 was able to increase the expression of Sp1 by binding to its promoter in colorectal cancer cells (40). Shi et al. (41) found that hepatitis B X-interacting protein may activate the fibroblast growth factor 4 promoter via Sp1, which then promotes the migration of breast cancer cells. The transcription activity of Sp1 is enhanced through direct phosphorylation of threonine by p42/p44 mitogen-activated protein kinase (42,43).
pancreatic and breast cancers (44-48). In the present study, the expression of Sp1 at mRNA and protein level to be upregulated in gastric cancer tissue, compared with that of normal gastric mucosa, suggesting that Sp1 expression contributes to gastric carcinogenesis. Sp1 expression was also found to be positively associated with depth of invasion, lymph node metastasis and TNM stage of gastric cancer, and the same was true for Sp1 mRNA expression, which indicates that aberrant Sp1 expression can be employed to indicate the pathological behavior of gastric cancers. This result shows that Sp1 mRNA gene expression levels may be used to predict corresponding protein levels.

Reportedly, Sp1 expression is positively related to the poor prognosis of patients with ovarian serous adenocarcinoma and colorectal cancer (49,50). Sp1 upreguation has also been shown to indicate a worse prognosis of breast cancer and hepatocellular carcinoma, as an independent factor (51,52). Chen et al (53) reported that the overall prognosis of patients with gastric cancer with high Sp1 levels is significantly poorer compared with that of those with low Sp1 levels. Our

| Clinicopathological features | Overall survival | Progression-free survival |
|------------------------------|-----------------|--------------------------|
|                              | Hazard ratio    | P-value                  | Hazard ratio    | P-value                  |
| Sex                          |                 |                          |                |                          |
| Female                       | 0.66 (0.39-1.11) | 0.11                     | 0.66 (0.40-1.09) | 0.10                    |
| Male                         | 0.63 (0.44-0.89) | 0.01                     | 0.57 (0.21-1.51) | 0.25                    |
| TNM staging                  |                 |                          |                |                          |
| 1                            | 0.19 (0.06-0.57) | <0.01                    | 0.17 (0.06-0.53) | <0.01                   |
| 2                            | 0.57 (0.26-1.24) | 0.15                     | 0.47 (0.21-1.06) | 0.06                    |
| 3                            | 0.60 (0.37-0.97) | 0.04                     | 0.66 (0.39-1.12) | 0.12                    |
| 4                            | 0.73 (0.43-1.25) | 0.25                     | 0.74 (0.50-1.08) | 0.12                    |
| T                            |                 |                          |                |                          |
| 2                            | 0.52 (0.37-0.87) | 0.01                     | 0.61 (0.38-1.00) | 0.05                    |
| 3                            | 1.29 (0.87-1.89) | 0.20                     | 1.31 (0.90-1.91) | 0.16                    |
| 4                            | 0.49 (0.20-1.20) | 0.11                     | 0.44 (0.19-1.01) | 0.05                    |
| N                            |                 |                          |                |                          |
| 0                            | 0.40 (0.16-0.97) | 0.04                     | 0.39 (0.16-0.94) | 0.03                    |
| 1-3                          | 0.62 (0.45-0.85) | <0.01                    | 0.65 (0.48-0.88) | <0.01                   |
| 1                            | 0.57 (0.35-0.94) | 0.02                     | 0.56 (0.34-0.92) | 0.02                    |
| 2                            | 0.54 (0.30-0.97) | 0.04                     | 0.56 (0.32-1.00) | 0.05                    |
| 3                            | 1.60 (0.84-3.04) | 0.15                     | 0.70 (0.40-1.22) | 0.21                    |
| M                            |                 |                          |                |                          |
| 0                            | 0.61 (0.43-0.85) | <0.01                    | 0.64 (0.46-0.88) | <0.01                   |
| 1                            | 0.61 (0.32-1.20) | 0.15                     | 0.62 (0.34-1.11) | 0.11                    |
| Perforation complications    |                 |                          |                |                          |
| -                            | 1.27 (0.85-1.90) | 0.25                     | 0.79 (0.53-1.18) | 0.25                    |
| Treatment                    |                 |                          |                |                          |
| Surgery alone                | 0.67 (0.48-0.94) | 0.02                     | 0.69 (0.49-0.97) | 0.033                   |
| 5-fluorouracil-based adjuvant| 4.36 (1.64-11.6) | <0.01                    | 3.22 (1.25-8.24) | 0.01                    |
| Other adjuvant               | 1.58 (0.63-3.96) | 0.3                      | 0.66 (0.28-1.54) | 0.34                    |
| Differentiation              |                 |                          |                |                          |
| Moderately-differentiated    | 0.48 (0.24-0.94) | 0.03                     | 0.45 (0.24-0.87) | 0.02                    |
| Poorly-differentiated        | 1.63 (0.98-2.70) | 0.06                     | 1.54 (0.95-2.50) | 0.08                    |
| Lauren's classification      |                 |                          |                |                          |
| Intestinal-type              | 0.50 (0.33-0.77) | <0.01                    | 0.52 (0.36-0.74) | <0.01                   |
| Diffuse-type                 | 1.43 (0.99-2.06) | 0.05                     | 1.36 (0.94-1.96) | 0.10                    |
| Mixed-type                   | 2.62 (0.57-12.02)| 0.20                     | 2.14 (0.59-7.83) | 0.24                    |
| Her2 positivity              |                 |                          |                |                          |
| -                            | 0.62 (0.47-0.81) | <0.01                    | 0.69 (0.49-0.98) | 0.04                    |
| +                            | 0.65 (0.41-1.02) | 0.06                     | 0.60 (0.37-0.98) | 0.04                    |
meta-analysis shows that Sp1 overexpression is associated with poor prognosis of human gastric carcinoma. Additionally, the results show that Sp1 mRNA expression is also positively associated with overall and progress-free survival rates of patients with gastric cancer.

Some limitations that exist in our meta-analysis. First, potential publication bias stems from the fact that published results were predominantly positive. Second, the patients included in the studies were only from Asia and America. Different levels of medical development in different areas may also influence the results as different experimental methods may have been used to detect Sp1 expression. Third, survival data were extracted from survival curves, which may affect the results. Fourth, small sample size may influence associations in some articles.

In conclusion, Sp1 protein expression is upregulated in gastric carcinogenesis. Sp1 is positively associated with the depth of invasion and TNM stage of gastric cancer. Sp1 protein expression can be employed as a good potential marker for the prognosis of patients with gastric cancer.

Acknowledgements

No applicable.

Funding

No funding was received.

Availability data and materials

The datasets generated and/or analyzed during the current study are available in the Oncomine database (www.oncomine.org) and Kaplan-Meier plotter (kmplot.com).

Authors’ contributions

SS and ZGZ extracted all the relevant information from the eligible publications, independently assessed the quality of the studies and wrote the manuscript. Both authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kadonaga JT, Carner KR, Masiarz FR and Tjian R: Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 51: 1079-1090, 1987.
2. Rodér K, Kim KH and Sul HS: Induction of murine H-rev107 gene expression by growth arrest and histone acetylation: Involvement of an Sp1/Sp3-binding GC-box. Biochem Biophys Res Commun 294: 63-70, 2002.
3. Samson SL and Wong NC: Role of Sp1 in insulin regulation of gene expression. J Mol Endocrinol 29: 265-279, 2002.
4. Safe S and Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438-2448, 2005.
5. Zaid A, Li R, Luciakova K, Barath P, Nery S and Nelson BD: On the role of the general transcription factor Sp1 in the activation and repression of diverse mammalian oxidative phosphorylation genes. J Bioenerg Biomembr 31: 129-135, 1999.
6. Duan H, Heckman CA and Linda MH: Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-1619, 2005.
7. Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T and Li F: Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: Evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem 280: 9745-9751, 2005.
8. Martin M, Le J and Delanlan S: TGF-beta1 and radiation fibrosis: A master switch and a specific therapeutic target? Int J Radiol Oncol Biol Phys 47: 277-290, 2000.
9. Jungert K, Buck A, Buchholz M, Wagner M, Adler L, Gress TM and Ellenrieder V: Smad-Sp1 complexes mediate TGFbeta-induced early transcription of oncogenic Smad in pancreatic cancer cells. Carcinogenesis 22: 209-214, 2001.
10. Wang S, Wang W, Wesly RA and Danner RL: A Sp1 binding site of the tumor necrosis factor alpha promoter functions as a nitrile oxide response element. J Biol Chem 274: 33190-33193, 1999.
11. Chae YS, Kim JG, Sohn SK, Cho YY, Moon JH, Bae HI, Park JY, Lee MH, Lee HC, Chung HY and Yu W: Investigation of the role of AP2 in luminal endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology 71: 266-272, 2006.
12. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J and Xie K: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 15: 4109-4117, 2009.
13. Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Horning HM, Lau-Werner U, Post S and Allgayer H: Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clin Cancer Res 13: 1123-1132, 2007.
14. Chen QN, Yuan P and Fan YZ: Expression of transcription factor Sp1 in pancreatic cancer and its relationship with prognosis. J Tongji Univ 30: 5-8, 2009.
15. Zhang W, Kadam S, Emerson BM and Bieker JF: Site-specific acetylation by p300 or CREB binding protein regulates erythroid Kruppel-like factor transcriptional activity via its interaction with the SWI-SNF complex. Mol Cell Biol 21: 2413-2422, 2001.
16. Chieffari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M and Filetti S: Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: A role in NIS expression regulation? BMC Cancer 35: 32, 2002.
17. Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, Nagawa H and Suzuki N: Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol 25: 461-468, 2004.
18. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H and Papa MZ: Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: Involvement of transcription factor Sp1. J Endocrinol 191: 605-612, 2006.
19. Han WD, Mu YM, Lu XC, Xu ZM, Li XJ, Yu L, Song HJ, Li M, Lu JM, Zhao YL and Pan CY: Up-regulation of LRP16 mRNA by Tbeta-estradiol through activation of estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of human breast cancer MCF-7 cell proliferation: A preliminary report. Endocr Relat Cancer 10: 217-224, 2003.
20. Marin M, Karis A, Visser P, Grosveld F and Philippen S: Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 89: 619-628, 1997.
21. Liu DC, Liang Q, Tao T, Huang QY, Xu B, Chen NG, Zhang ZG, Dong Y, Han CH and Chen M: Sp1 promotes cell metabolism and proliferation through PKM2 pathway in prostate cancer. J Southeast Univ (Med Sci Edi ) 10: 337-341, 2015.
23. Hao C and Meng A: Spl-like transcription factors are regulators of embryonic development in vertebrates. Dev Growth Differ 47: 201-211, 2005.

24. Homas K, Wu J, Sung DY, Thompson W, Powell M, McCarthy J, Gibriss R and Walker W: SPI transcription factors in male germ cell development and differentiation. Mol Cell Endocrinol 270: 1-7, 2007.

25. Wei YZ, Li CF and Xue YW: Expression of transcription factor SPI1, vascular endothelial growth factor and CD34 in serosa-infiltrating gastric cancer and their relationship with biological behavior and prognosis. Zhonghua Wei Chang Kwei Za Zhi 12: 145-149, 2009 (In Chinese).

26. Wang LW, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J and Xie K: Transcription factor SPI expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9: 6371-6380, 2003.

27. Hua ZL, Zhu YC, Guo GP, Ling RB, Zhou Q and Shi AW: Expression of transcription factors in gastric cancer and its relationship with clinical pathology. Med Imaging 9: 162-163, 2013.

28. Zhang J, Zhu ZG, Ji J, Yuan F, Yu YY, Liu BY and Lin YZ: Transcription factor SPI expression in gastric cancer and its relationship to long-term prognosis. World J Gastroenterol 11: 2213-2217, 2005.

29. Zhang PC, Liang L, Zhang DK, Yao BH, Song L, Li Y and Zhao JS: Expression and significance of transcription factor SPI and Stat-3 in gastric carcinoma. Chin J Gen Surg 25: 1714-1716, 2014.

30. Zhang RR: Expression of correlation relationship and significance of SPI, Notch1 and KLF4 in gastric cancer. Maser Thesis, Shanxi Med Univ China, 2011.

31. A JD: The clinical study on expression and significance of Spi protein in gastric carcinoma. Master Thesis, Qinghai Univ China, 2011.

32. Zou HH, Wu XM and Ye CJ: Expression of matrix metalloproteinase-11 and the transcription factor SPI in gastric cancer. J Qinghai Med College 36: 49-53, 2015.

33. Jiang MZ: Study about the expression and significance of KLF5, SPI and CyclinD1 in carcinoma of stomach. Kunming. Maser Thesis, Med Univ China, 2009.

34. Jiang W, Jin Z, Zhou F, Cui J, Wang L and Wang L: High co-expression of SPI and HER-2 is correlated with poor prognosis of gastric cancer patients. Surg Oncol 24: 220-225, 2015.

35. Cui JF, Zhao CY, Cao LY, Wu WN, Li YH, Wang Y, Xue LY and Zhang XG: Comparison of KLF4, SPI, and Cyclin D1 expressions between ad-eno-carcinoma of the esophagogastric junction and distant gastric adenocarcinoma. Chin J Clin Oncol 41: 108-112, 2014.

36. Lee HS, Park CK, Oh E, Erkin OC, Jung HS, Cho MH, Kwon MJ, Chae SW, Kim SH, Wang LH, et al: Low SPI expression differentially affects intestinal-type compared with diffuse-type gastric adenocarcinoma. PLoS One 8: e55522, 2013.

37. Kumar AP and Butler AP: Serum responsive gene expression mediated by SPI. Biochem Biophys Res Commun 252: 517-523, 1998.

38. Chen F, Zhang F, Rao J and Studzinski GP: Ectopic expression of truncated SPI transcription factor prolongs the S phase and reduces the growth rate. Anticancer Res 20: 661-667, 2000.

39. Peng H, Li Y, Liu Y, Zhang J, Chen K, Huang A and Tang H: HBx and SPI upregulate DKK1 expression. Acta Biochim Pol 64: 35-39, 2017.

40. Yu MH and Zhang W: TEAD1 enhances proliferation via activating SPI1 in colorectal cancer. Biomed Pharmacother 83: 496-501, 2016.

41. Shi H, Li Y, Peng G, Li L, Fang R, Wang Z, Qu J, Ding P, Zhang X and Ye L: The oncoprotein HBXIP up-regulates FGF4 through activating transcriptional factor SPI to promote the migration of breast cancer cells. Biochem Biophys Res Commun 471: 89-94, 2016.

42. Milanini-Mongiat J, Pouyssegur J and Pagès G: Identification of two SPI phosphorylation sites for p42/p44 mitogen-activated protein kinases. Their implication in vascular endothelial growth factor gene transcription. J Biol Chem 277: 20631-20639, 2002.

43. Merchant JL, Du M and Todisco A: SPI phosphorylation by Erk 2 stimulates DNA binding. Biochem Biophys Res Commun 254: 454-461, 1999.

44. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of SPI transcription factor activity. Cancer Res 64: 2030-2038, 2004.

45. Zhao S, Venkatasubbarao K, Li S and Freeman JW: Requirement of a specific SPI site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. Cancer Res 63: 2624-2630, 2003.

46. Suske G: The Sp-family of transcription factors. Gene 238: 291-300, 1999.

47. Wright C, Angus B, Napier J, Wetherall M, Udagawa Y, Sainsbury JR, Johnston S, Carpenter F and Horne CH: Prognostic factors in breast cancer: Immunohistochemical staining for SPI and NCRC 11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status. J Pathol 153: 325-331, 1987.

48. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC and Xie K: Constitutive SPI activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61: 4143-4154, 2001.

49. Zhang J, Jiang RX, Fan XM, Lou L, Liu WN, Zhao XW and Li YH: Expression and prognostic significance of SPI, KLF4 and p21 in the ovary serous adenocarcinoma. J Clin Exp Pathol 33: 22-26, 2017.

50. Liu CF, Ji YC, Sun YY and Li XD: Expression of SPI1 in colorectal cancer and its relation ship with biological behavior and prognosis. Chin J Gastroenterol Hepatol 20: 51-53, 2011.

51. Wang XB, Peng WQ, Yi ZJ, Zhu SL and Gan QH: Expression and prognostic value of transcriptional factor spi1 in breast cancer. Ai Zhi 26: 996-1000, 2007 (In Chinese).

52. Fan Q, Zhu K, Chen WY, Zhang JB, Sun HC, Wang L and Ren N: Correlation of transcription factor SPI expression with clinical and pathological characteristics and prognosis of hepatocellular carcinoma. Chin J Clin Oncol 41: 1284-1287, 2014.

53. Chen QX, Yuan P, FanYZ, et al: Expression of transcription factor SPI1 in human pancreatic ductal carcinoma and its relationship with prognosis. J Tongji Univ (Med Sci) 30: 5-8, 2009.